BIOS

Uniting the Life Science Ecosystem In #PatientImpact — Highlighting Industry Leaders Shaping The Future Of Medicine✨By: @alixventures

[BIOS @bios_community]

BIOS — Top 100 TechBio VC Funds 🧬

As TechBio reaches critical mass, we thought it time to centralize the world of TechBio VC into one sheet

We hope this database becomes a useful resource & serves as a go to for founders raising VC Funding…

https://t.co/MA7xN3rmpc

[64x Bio @64xbio]

New product launch: Today we’re launching LV Apex Suite, a new product suite for lentiviral vector production.

This marks 64x Bio’s expansion from AAV into LV — and another step in translating our CellMap-driven VectorSelect platform across new modalities.

LV Apex Suite begins with a high yield engineered HEK293T suspension cell line for transient LV production, with stable systems and additional production-enabling technologies in development.

More broadly, this launch reflects where 64x Bio is headed: expanding CellMap as a data foundation for production biology, and learning from those data computationally to iteratively guide development of better cell lines, reagents, and production systems for viral vectors — and soon, biologics.

To learn more about LV Apex Suite, read our press release below and visit https://t.co/95gQiMpjxk.

Press release: https://t.co/C1BOGTYPnU

[Lexi Rovner @lexrovner]

We’re launching LV Apex Suite today, our second Apex Suite after AAV. Each new modality adds data on what’s shared, what’s different, and how to engineer production systems in an integrated way. That’s tied to a core view at @64xbio:

Cell lines, reagents, and process aren't separate levers, they're interdependent parts of a single production system. If we want better productivity, quality, and scalability, we need to understand and engineer that system more holistically.

That’s what we’re building toward with CellMap: data-rich experimental maps of production biology that we can learn from computationally, to guide the design of better cell lines and reagents. Biologics are next, and existing suites will keep expanding with additional tools.

With this, we’re also growing our commercial and ops teams. If you’re excited about building next gen biomanufacturing tools, DM me.

Incredibly proud of the team today for all the work behind this launch. Much more to come.

[Strand Therapeutics @StrandTx]

We're excited to welcome @JebKeiper to Strand's Board as an independent Director!

Strand gains invaluable expertise from Jeb, whose proven track record as former CEO of Nimbus Therapeutics encompasses preclinical R&D innovation, clinical development, and global business development and licensing. With him on board, we’re driving the future of genetic medicines forward.

Read more: https://t.co/E7QZt7Dzwc

[BIOS @bios_community]

Landscape #2: Future of Gene Therapy

Gene therapy is more than just a breakthrough for rare monogenic diseases—it's the foundation for a new era in medicine. While current therapies focus on introducing wildtype genes to counteract loss of function mutations, the potential for broader, more complex treatments is immense. The future of gene therapy could redefine how we treat serious diseases, making it a key player in the future of healthcare

Read more: https://t.co/eeq8fSqprS

[BIOS @bios_community]

@BigHatBio @MarkDePristo 🌍 What’s next for @BigHatBio? Discover how they’re building a drug development machine that could revolutionize medicine. Tune in

[BIOS @bios_community]

Builders #4 w/ Mark DePristo & Peyton Greenside - Co-Founders @ BigHat Biosciences

🔍 What sparked the idea behind @BigHatBio? Find out how @MarkDePristo & Peyton combined AI/ML with fast data generation to revolutionize protein therapeutics. This episode is a must-listen for anyone interested in the future of biologics.

Tune in: https://t.co/263iGmaESo

[BIOS @bios_community]

@BigHatBio @MarkDePristo Join us as @BigHatBio’s @MarkDePristo & Peyton Greenside discuss how they’re harnessing AI to create better biologics and improve human health. From the origins of BigHat to their cutting-edge platform.

[BIOS @bios_community]

Imagine a world where we deeply understand cancer, manage our immune systems proactively, and invest in health early. Jennifer Friel Goldstein explores this vision for biotech 2050, where breakthroughs are fueled by novel capital strategies and diverse ecosystems. 🌟

[BIOS @bios_community]

Advancing women's health and diversity in Biotech: Jenniffer Friel Goldman @ SVB Capital

Jennifer Friel Goldstein shares her vision for the future of biotech, where diversity in leadership, capital efficiency, and innovative tools drive a healthcare revolution. From rethinking women's health to empowering Femtech and embracing preventive care, the future is transformative. 🚀

[BIOS @bios_community]

With women leading health decisions and unmet needs driving innovation, Femtech and digital health are rising fast. Jennifer Friel Goldstein discusses how the future of healthcare lies in inclusive leadership, efficient capital, and breaking down traditional barriers. 🌐💡

#Femtech #DigitalHealth #HealthcareInnovation

[BIOS @bios_community]

Landscape: Future of Cell Therapy 🧬

Accelerating gene circuit development in cell therapy! High-throughput tools are revolutionizing design, paving the way for personalized Trx. Explore this perspective & projections on its impact.

Read more: https://t.co/abKUgLgOtN

[BIOS @bios_community]

@AlloyTx 🔥 What’s next for Alloy Therapeutics? Get insights from Errik Anderson on the future of biotech and how @AlloyTxis leading the charge in developing breakthrough therapies. Listen in!

[BIOS @bios_community]

Builders w/ Errik Anderson - Founder & CEO @ Alloy Therapeutics

Ever wondered what it takes to build a 'forever company' in biotech? Errik Anderson shares the genesis of @AlloyTx, detailing how they’re creating a collaborative ecosystem with over 100 partnerships and counting. Learn how their platforms, like ATX-Gx for antibody discovery, and strategic acquisitions like deepCDR Biologics, are setting new standards in the field. Tune in for a visionary look at the future of drug discovery. 🎧

Tune in: https://t.co/DsrW1wzHiQ

#LifeSciences #BiotechEcosystem

[BIOS @bios_community]

@AlloyTx Discover the science behind @AlloyTx's ATX-Gx platform for antibody discovery and what makes their humanized mice unique. Errik Anderson explains how Alloy is pushing the boundaries of drug discovery. Listen to the full episode! 🧬

[BIOS @bios_community]

What does the future hold for biotech? 🤔 David Schaffer envisions a world where advances in gene therapies, synthetic biology, and precision medicine reshape how we treat diseases—from neurodegeneration to cancer. But with this incredible potential comes the need for careful ethical oversight. As we unlock the ability to reprogram cells and edit human genomes, how do we ensure these technologies are used responsibly? 🧬🛡️

In this episode, David explores the balance between accelerating innovation and navigating the ethical challenges, like equitable access to treatments, the implications of gene editing, and the risks of dual-use technologies.

[BIOS @bios_community]

Genetic and Cellular Engineering w/ David Schaffer - Prof @ Berkeley

Join us as David Schaffer dives deep into the evolution of AAV delivery systems, the founding story of @4DMT, and the grand challenges in life sciences over the next 20 years. A visionary discussion on the future of medicine!

Tune in: https://t.co/8VvXG2hVa4

[BIOS @bios_community]

@4dmt How does a research culture foster groundbreaking biotech innovation? David Schaffer shares insights from leading QB3, the Schaffer Lab, & more.

[BIOS @bios_community]

BIOS Nobel: A Deep Dive into the Life Sciences Through the Eyes of Nobel Prize Recipients

🌟📜 Get inspired by iconic quotes and deep dives into the discoveries that earned Nobel Prizes in life sciences. Learn more in our new series: Wisdom of the Laureates! 🚀

Read more: https://t.co/sEjxUdnYL0

#NobelPrize #ScienceExploration #WisdomSeries

[BIOS @bios_community]

@NautilusBio The human proteome is a vast, largely uncharted territory in drug discovery. Learn how @NautilusBio's proprietary platform is decoding complex protein interactions to uncover new therapeutic targets, paving the way for next-gen precision medicine.

[BIOS @bios_community]

Builders w/ Sujal Patel & Parag Mallick - Co-Founders @ Nautilus Biotechnology

@NautilusBio co-founders Sujal Patel & Parag Mallick share their journey from the initial spark to going public via a SPAC in 2021. Discover the challenges, triumphs, and what lies ahead in the proteomics revolution.

Tune in: https://t.co/92b0nQkUP9

[BIOS @bios_community]

@NautilusBio 🔮 The Future of Proteomics
What’s next for @NautilusBio and the field of proteomics? Tune in to hear Sujal & Parag’s vision for the future and how it could revolutionize biomedicine.